Logo
x

Search

Subscribe Now

Approval 

Novartis’ Pluvicto (177Lu-PSMA-617) Received the US FDA’s Approval as the First Targeted Radioligand Therapy for Progressive, PSMA Positive mCRPC

Novartis’ Pluvicto (177Lu-PSMA-617) Received the US FDA’s Approval as the First Targeted Radioligand Therapy for Progressive, PSMA...

  • March 23, 2022
Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial C...

  • September 27, 2021
Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

  • September 22, 2021
Exelixis' Cabometyx (cabozantinib) Receives the US FDA's Approval for the Treatment of Locally Advanced or Metastatic Differentiated Thyroid Cancer

Exelixis' Cabometyx (cabozantinib) Receives the US FDA's Approval for the Treatment of Locally Advanced or Metastatic Differentiat...

  • September 20, 2021
Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Amgen's Lumakras (sotorasib) Receives Health Canada's Approval for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell...

  • September 14, 2021
Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine

Impel NeuroPharma's Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA's Approval for the Treatment of Migraine

  • September 7, 2021
Daiichi Sankyo’s Vanflyta (quizartinib) Receives the MHLW’s Approval for Newly Diagnosed FLT3-ITD Positive AML

    Daiichi Sankyo’s Vanflyta (quizartinib) Receives the MHLW’s Approval for Newly Diagnosed FLT3-ITD Positive AML

    • May 26, 2023
    Blueprint Medicines’ Ayvakit (avapritinib) Receives the US FDA’s Approval as the First Treatment for Indolent Systemic Mastocytosis

      Blueprint Medicines’ Ayvakit (avapritinib) Receives the US FDA’s Approval as the First Treatment for Indolent Systemic Mastocytosi...

      • May 23, 2023
      Braeburn

        Braeburn's Brixadi (buprenorphine) Receives the US FDA’s Approval for Moderate to Severe Opioid Use Disorder

        • May 23, 2023
        Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the US FDA’s Approval for Dystrophic Epidermolysis Bullosa in Patients Aged ≥6 Months

          Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the US FDA’s Approval for Dystrophic Epidermolysis Bullosa in Patients...

          • May 22, 2023
          Abbott’s Spinal Cord Stimulation Systems Receives the US FDA’s Approval for Chronic Back Pain

            Abbott’s Spinal Cord Stimulation Systems Receives the US FDA’s Approval for Chronic Back Pain

            • May 17, 2023
            Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due to Alzheimer’s Disease

              Otsuka and Lundbeck Receive the US FDA’s Approval for Rexulti (brexpiprazole) sNDA to Treat Agitation Associated with Dementia Due...

              • May 12, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.